I am pleased to share with you the link to our new publication about Integrated Valuation Model. This is the first paper that is integrating the payer’s perspective and the investor’s perspective. The practical strategic application of this “value for access to market model” (V4A2M Model) is optimization of positioning and price of innovative product. Hence, it can be a transparent tool in early-stage development of a compound for an upfront assessment of its market access attractiveness for the payer and the investor, and for early phase strategic decisions about indication, trial design, positioning and pricing. We applied the concept in this paper to oncology, but it was also developed especially for orphan drugs.https://www.tandfonline.com/doi/full/10.1080/20016689.2022.2080631
